Can you take Afamitresgene autoleucel with Meningococcal conjugate vaccine?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- afamitresgene autoleucel
- meningococcal conjugate vaccine
Drug interactions
Moderate drug interactions
Moderate:
meningococcal conjugate vaccine afamitresgene autoleucel
Applies to: meningococcal conjugate vaccine and afamitresgene autoleucel
If you are currently being treated or have recently been treated with afamitresgene autoleucel, you should let your doctor know before receiving meningococcal conjugate vaccine. Depending on the dose and length of time you have been on afamitresgene autoleucel, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of afamitresgene autoleucel therapy. If you have recently been vaccinated with meningococcal conjugate vaccine, your doctor may choose to postpone treatment with afamitresgene autoleucel for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
8 potential interactions Applies to: 8 conditions, including Liver Disease, Infection, Thrombocytopenia, Immunodeficiency, and Guillain-Barre Syndrome.
Coagulation Defects and Disorders
Moderate:
meningococcal conjugate vaccine
Meningococcal conjugate vaccine has a moderate potential interaction with Coagulation Defects and Disorders.
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Guillain-Barre Syndrome
Moderate:
meningococcal conjugate vaccine
Meningococcal conjugate vaccine has a moderate potential interaction with Guillain-Barre Syndrome.
Persons previously diagnosed with Guillain-Barre syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.
Immunodeficiency
Moderate:
meningococcal conjugate vaccine
Meningococcal conjugate vaccine has a moderate potential interaction with Immunodeficiency.
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
Infection
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Infection.
Afamitresgene autoleucel is not recommended in patients with active infections. Additionally, this drug may cause viral reactivation. Patients should be screened for presence of viral and infectious agents (e.g., Epstein-Barr Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus) if clinically indicated. Monitor for signs and symptoms of infection before and after treatment. Consider antiviral therapy to prevent viral reactivation per local guidelines.
Liver Disease
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Liver Disease.
Afamitresgene autoleucel has not been studied in patients with any degree of hepatic impairment.
Renal Dysfunction
Moderate:
afamitresgene autoleucel
Afamitresgene autoleucel has a moderate potential interaction with Renal Dysfunction.
Afamitresgene autoleucel has not been studied in patients with any degree of renal impairment.
Thrombocytopathy
Moderate:
meningococcal conjugate vaccine
Meningococcal conjugate vaccine has a moderate potential interaction with Thrombocytopathy.
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Thrombocytopenia
Moderate:
meningococcal conjugate vaccine
Meningococcal conjugate vaccine has a moderate potential interaction with Thrombocytopenia.
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Report options
More resources
afamitresgene autoleucel
A total of 200 drugs are known to interact with afamitresgene autoleucel.
- Afamitresgene autoleucel is in the drug class miscellaneous antineoplastic cell and gene therapies.
- Afamitresgene autoleucel is used to treat Synovial Sarcoma.
meningococcal conjugate vaccine
A total of 340 drugs are known to interact with meningococcal conjugate vaccine.
- Meningococcal conjugate vaccine is in the drug class bacterial vaccines.
- Meningococcal conjugate vaccine is used to treat Meningococcal Disease Prophylaxis.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.